Boehringer Ingelheim USFDA Approval
Boehringer Ingelheim JASCAYD® (nerandomilast) tablets are approved by the U.S. FDA as an oral treatment for idiopathic pulmonary fibrosis (IPF) in adult patients. JASCAYD is the first and only preferential inhibitor of phosphodiesterase 4B (PDE4B) to be approved in this indication.
This represents a novel mechanism of action that exerts both antifibrotic and immunomodulatory effects, thereby slowing the decline in lung function in IPF patients.
From the Experts
Toby Maher, M.D., Ph.D., Professor of Clinical Medicine, Keck School of Medicine, USC Los Angeles. Said, “This milestone represents a new era in . . .
This content is for paid subscribers.
Impacting News
October 16, 2025
 Tablets as First New Treatment for Adults with Idiopathic Pulmonary Fibrosis){kind=link}